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Hemodynamic response to primary prophylactic
therapy with nonselective β-blockers is related
to a reduction of first variceal bleeding risk in liver
cirrhosis: a meta-analysis
Annarein J.C. Kerberta,*, Fang W.T. Chianga,*, Mark van der Werfb, Theo Stijnenb, Hilde Slingerlanda,
Hein W. Verspageta, Bart van Hoeka and Minneke J. Coenraada
The current primary prophylaxis for esophageal variceal bleeding in cirrhotic patients consists of nonselective β-blocker (NSBB)
therapy. However, only approximately half of the patients achieve a sufficient hemodynamic response to NSBB therapy. Clinical
application of hemodynamic response monitoring is still under debate. The aim of this meta-analysis is to assess the potential
clinical value of monitoring the hemodynamic response to NSBB therapy using hepatic venous pressure gradient (HVPG)
measurements in the primary prophylaxis for variceal bleeding. A systematic literature search was performed in PubMed,
Embase, Web of Science, and the COCHRANE Library. Randomized-controlled trials and case series that included cirrhotic
patients receiving primary prophylaxis for variceal bleeding with NSBBs and hemodynamic response monitoring using HVPG
measurements were included for analysis. The primary outcome measure was variceal bleeding. A fixed-effect analysis was
carried out using the Mantel–Haenszel method for relative risks. Six of the 1172 papers found were selected on the basis of
stringent selection criteria. Hemodynamic response (HVPG ≤12mmHg and/or a reduction of ≥20%, or ≥10% in one study,
from baseline) to β-blocker therapy was associated significantly with a lower risk of variceal bleeding (relative risk=0.13, 95%
confidence interval=0.06–0.29) compared with a nonresponse. Patients achieving a hemodynamic response to NSBB therapy
have a lower risk of variceal bleeding than hemodynamic nonresponders. Hemodynamic monitoring in primary prophylaxis is of
potential clinical value and requires further assessment in large cohort randomized-controlled trials. Eur J Gastroenterol Hepatol
29:380–387
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Introduction
Esophageal varices are common in cirrhotic patients with
portal hypertension with a prevalence of ∼ 50% [1]. Acute
variceal bleeding occurs at an annual rate of 5–15% per
year and is the most common lethal complication in cir-
rhosis. It is associated with a 6-week mortality rate of 20%
[1] and with rebleeding rates of 60–70% within the first
2 years in the absence of secondary prophylactic treatment
[2]. Therapeutic options to prevent a first bleeding episode
include pharmacological therapy with nonselective β-
blockers (NSBBs), endoscopic band ligation, and place-
ment of transjugular intrahepatic portosystemic shunts [3].
Primary prophylaxis with NSBBs is currently recom-
mended as the standard of care in cirrhotic patients with
medium-large varices and patients with small varices who
are at an increased risk of bleeding [4]. NSBBs reduce
portal pressure by decreasing cardiac output and produ-
cing splanchnic vasoconstriction. Treatment with NSBBs
decreases the risk of a first bleeding episode by ∼50% in
various studies [5,6]. However, reduction of the heart
frequency by NSBB therapy and reduction in portal venous
pressure are not correlated [7]. Measurement of the
hepatic venous pressure gradient (HVPG) is currently the
most commonly used method to determine the presence
and severity of portal hypertension [8–10]. An HVPG of at
least 10mmHg is considered clinically significant portal
hypertension at which complications such as the develop-
ment of esophageal varices may occur. Various studies
have shown that a reduction of the HVPG up to 12mmHg
or of at least 10–20% from baseline is associated with a
significantly decreased risk of a variceal bleeding episode
[11–13]. However, only 50% of patients treated with
NSBBs achieve this hemodynamic response [14]. HVPG
measurement can guide prophylactic therapy by identifi-
cation of hemodynamically nonresponding patients to pro-
vide add-on or alternative therapy in this subgroup [14,15].
The clinical application of HVPG measurement in the
prevention of variceal bleeding with NSBBs is still under
debate [16–20]. A previous meta-analysis [14] and sys-
tematic review [16] showed that a reduction of the HVPG
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provides valuable prognostic information in the setting of
primary and secondary prophylaxis for variceal bleeding.
More recently, the use of HPVG was recommended in the
Baveno VI consensus [4]. In clinical practice, HVPG
monitoring of primary prophylactic therapy with NSBBs is
not widely implemented because of the lack of evidence,
experience, and costs. The aim of this meta-analysis is to
assess the prognostic value of monitoring the hemody-
namic response to NSBB therapy using HVPG measure-




A systematic literature search was performed to identify
eligible studies (date of the search: 9 March 2016).
Assisted by a trained librarian, a search was performed in
the following databases: PubMed, Embase (OVID ver-
sion), Web of Science, and the COCHRANE Library. The
subject query was applied to all databases taking into
account the terminological differences between them. The
query consisted of the following subjects: ‘liver cirrhosis’,
‘esophageal varices’, ‘blood pressure’, ‘β-blockers’, and
‘prophylaxis’. Various synonyms and related terms for all
subjects were used in the search (Supplementary Table 1,
Supplemental digital content 1, http://links.lww.com/
EJGH/A159). For the articles included, an additional
citation tracking search was performed for unique refer-
ences that were not found in the initial systemic search.
Study selection
Titles, abstracts, and full articles were screened indepen-
dently for eligibility by two authors. Disagreement
between reviewers was resolved through consensus.
Exclusion criteria were as follows: studies unrelated to
variceal bleeding, pediatric and experimental studies, stu-
dies on secondary prevention (i.e. patients with a previous
variceal bleeding episode), and study designs other than
randomized-controlled trials and prospective case series.
Conference abstracts were also included in the literature
search. In case of duplicate data or results published in
multiple studies, the most recent and/or complete data
were included for data extraction and analysis. Specific
reasons for excluding studies are shown in Fig. 1. Study
quality of the nonrandomized studies selected for meta-
analysis was assessed using the Newcastle–Ottawa Scale
for observational studies [21]. This scale is designed to
assess the risk of bias in three domains: patient selection,
comparability of study groups, and the ascertainment of
either the exposure or outcome of interest for case–control
studies or cohort studies, respectively.
Data extraction
The following data were extracted from the studies inclu-
ded: study design, number of included and evaluated
patients, etiology of cirrhosis, Child–Pugh score, specific
type of prophylaxis used, hemodynamic response to ther-
apy, number of variceal bleeding episodes (subdivided on
the basis of hemodynamic response), mean value of base-
line HVPG, time to remeasurement, and follow-up time.
Hemodynamic response was defined as a reduction in
HVPG up to 12mmHg or of at least 20% from baseline in
all studies. One study [22] applied a cut-off value of an
HVPG up to 12mmHg or a decrease of at least 10% from
baseline. We applied the definitions of hemodynamic
response identical to those applied in the individual
selected studies as described above.
Statistical analysis
The primary outcome measure was a first variceal bleeding
episode during follow-up. The number of first variceal
bleeding episodes was recorded for both the responder and
the nonresponder group. The pooled relative risk (RR)
with a 95% confidence interval (CI) for responders versus
nonresponders was estimated by meta-analysis using fixed-
effect and random-effects models. Statistical heterogeneity
of the studies was evaluated to determine whether to apply
a fixed-effect or a random-effects model. The heterogeneity
was estimated by calculating the residual between-trial
variance τ using a restricted maximum likelihood method.
The estimated τ was 0.00 and the Cochrane χ2-test indi-
cated no significant heterogeneity (P= 0.77). Therefore,
the random-effects model was reduced to a fixed-effects
model. The model was fitted using the natural log of the
risk ratios of the individual studies, which were weighed
using inverse variance. As the assumption of normality of
the log risk ratios could be violated, an additional fixed-
effects analysis was carried out using the Mantel–Haenszel
method. This method is less biased and especially more
advantageous in small sample sizes, which is the case for
the studies included [23].
Results
Literature search
The bibliographic databases yielded a total of 1172
references, which were screened for eligibility. In total, 977
abstracts were assessed after title screening. Editorials,
letters, reviews, overviews, opinions, and case reports were
excluded from further assessment. Abstracts unrelated to
pharmacological prophylaxis of variceal bleeding were
also excluded. 104 full articles were selected for a detailed
review. The reasons for the exclusion of 98 of these articles
are shown in Fig. 1. One study [24] that fulfilled the
selection criteria was excluded from meta-analysis because
of the small study population and the absence of bleeding
events in both the responder and the nonresponder group.
Finally, six peer-reviewed articles, including a total of 308
patients, were selected for the final analysis (Fig. 1). An
additional 287 unique articles were found through citation
tracking of these included articles, but of these, no eligible
papers were selected after screening.
Study characteristics
The study characteristics of the selected papers are out-
lined in Tables 1 and 2. The selected papers included one
randomized-controlled trial [12] and five prospective
nonrandomized case series [15,22,25–27]. The mean
Newcastle–Ottawa Scale score was 7.6 (range: 7–8) for the
five nonrandomized studies (Supplementary Table 2, Supple-
mental digital content 2, http://links.lww.com/EJGH/A159).
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All patients (n=414) were treated with NSBBs, either
propranolol or nadolol. In two of the studies, organic
nitrates were added if patients did not achieve the target
hemodynamic response to NSBBs alone [15,25]. In these
studies, a total of 39 patients received organic nitrates; of
these, 10 (25.6%) patients ultimately achieved a hemo-
dynamic response. These patients were analyzed in the
hemodynamic response group together with patients who
responded to NSBB monotherapy. In the study of Merkel
et al. [25], 20 patients received organic nitrates irrespective
of the presence of a hemodynamic response.
Classification of varices was variable between the trials.
Two studies included patients with varices irrespective of
their size or classification [12,26]. Villanueva et al. [22]
only included patients with large varices (i.e. ≥5mm),
whereas Merkel et al. [25] included patients with both
large varices and small varices (i.e. < 5mm) with red whale
signs. Bureau et al. [15] and Sharma et al. [27] included
only patients with varices of grade II or III and grade III or
IV, respectively.
The time interval between the first and second HVPG
measurement differed among the studies included. Four
studies carried out the second measurement at ∼1 month
after baseline measurement, whereas two studies repeated
the HVPG measurement after 3 and 4 months, respectively
(Table 2).
Variceal bleeding and hemodynamic response
The correlation between variceal bleeding and hemody-
namic response to NSBBs was calculated by combining the
data of the six studies. Table 3 summarizes the proportions
of variceal bleeding episodes in relation to the development
of a hemodynamic response on primary prophylaxis in the
individual studies. Of all 414 patients included in the six
selected studies, 308 (74.4%) patients were evaluated in
the final meta-analysis assessing the relative risk for a first
variceal bleeding episode in hemodynamic responders
versus nonresponders to NSBB treatment. Specifications of
reasons for excluding subgroups of patients from the final
meta-analysis as reported by the authors of the six inclu-
ded studies are shown in Supplementary Table 3,
Supplemental digital content 3, http://links.lww.com/
EJGH/A159. In total, 157 out of the 308 (50.9%) eval-
uated patients achieved a hemodynamic response to
pharmacological prophylaxis. The proportion of bleeding
episodes in the hemodynamic response group was six out
of 157 (3.8%) patients. In the nonresponding group, 42
out of 151 [27.8%, (Table 3)] patients had a bleeding
episode. The occurrence of a bleeding episode during
follow-up in the subgroups of patients treated with pro-
pranolol in combination with organic nitrates was not
specified in the respective studies.
1172 titles found through literature search
982 abstracts reviewed
878 excluded:
Reviews, editorials, comments, letters (394); Non-English paper (203); 
Secondary prophylaxis (78); Endoscopic prophylaxis (62); Treatment of 
active variceal bleeding (24); Physiological/diagnostic/decision analysis 
studies (83); TIPS or surgical prophylaxis (14); No NSBB prophylaxis (20)
104 articles fully assessed
190 titles excluded:
Animal studies (19); Pediatric studies (27); Studies unrelated to variceal 
bleeding (144)
6 peer-reviewed articles selected for meta-analysis
98 excluded:
No HVPG (34); Bleeding no endpoint (28); Duplicate data (4); No definition 
hemodynamic response (10); Incomplete data (12); No events (1); Separate 
analysis of data on primary and secondary prophylaxis not possible (1); Prior 
pharmacological treatment (2); Insufficient data (6)
Fig. 1. Flowchart showing the selection process of the retrieved studies for meta-analysis of hemodynamic monitoring of pharmacological primary prophylaxis
for variceal bleeding in cirrhosis. HVPG, hepatic venous pressure gradient; NSBB, nonselective β-blocker; TIPS, transjugular intrahepatic portosystemic shunt.
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The RR of bleeding in hemodynamic responders com-
pared with nonresponders was 0.13 (95% CI: 0.06–0.29)
through a fixed-effect analysis with the Mantel–Haenszel
method (Fig. 2). No significant heterogeneity in RR was
found between the studies (P= 0.77). Applying the defi-
nition of at least 20% HVPG reduction from baseline also
for the study of Villanueva et al. [22], the RR of bleeding
in hemodynamic responders became 0.14 (95% CI:
0.05–0.35). Conditional logistic regression showed that
the RR was not dependent on the median time to remea-
surement (P=0.39).
Discussion
Portal hypertension in liver cirrhosis is a progressive con-
dition, leading to the development of esophageal varices at
a rate of ∼ 7% per year [28,29]. HVPG measurement is the
gold-standard method to assess the presence of portal
hypertension [4]. The threshold HVPG value at which
gastroesophageal varices develop is 10mmHg. These
patients are referred to as having clinically significant
portal hypertension. A noninvasive assessment of clinically
significant portal hypertension by measuring liver stiffness
using transient elastography is currently only considered
sufficient in patients with viral-related chronic liver dis-
ease. In addition, the degree of liver stiffness can, together
with platelet count, predict the risk of the presence of
gastroesophageal varices. Therefore, transient elasto-
graphy can also be used to identify patients who should
undergo screening esophagogastroduodenoscopy [4]. The
risk of bleeding from esophageal varices is largely depen-
dent on their size, which is the most commonly used factor
in clinical practice to identify patients who are at a high
risk of bleeding. Patients with small varices (< 5mm) have
a bleeding risk of ∼ 12% in the first 2 years after diagnosis
compared with 30% in patients with medium-large varices
(≥5mm) [29–31]. Other important risk factors for variceal
bleeding include the severity of the underlying liver disease,
as defined by the Child–Pugh score, and the presence of
red wale marks on the variceal wall [32]. To improve the
ability of risk assessment for variceal bleeding, several
other factors have been explored, such as variceal wall
tension [33] and portal pressure [34,35], as reflected by the
HVPG. It has been found that the level of the HVPG sig-
nificantly improves the prediction of variceal bleeding risk
[35,36]. Primary prophylaxis with NSBBs, which is the
first-choice treatment option [4], is based on its ability to
decrease portal blood flow by reducing cardiac output
and inducing splanchnic vasoconstriction, resulting in
decreased variceal wall tension. It has been proven that
NSBB therapy significantly reduces the risk of a first
bleeding episode compared with nontreated patients: ∼20
versus ∼35% bleeding risk within 2 years of diagnosis [14,37].
NSBB therapy achieves a target reduction of the HVPG up
to 12mmHg or a reduction of more than 20% from
baseline in ∼ 50% of patients [14]. A previous meta-
analysis by Albillos et al. [14] showed that hemodynamic
responders are at a significantly lower risk of developing a
first bleeding episode than nonresponders (6 vs. 32%).
This was confirmed in the present meta-analysis, which
included more recent data and a higher number of study
participants compared with the previous meta-analysis.
These findings imply that it might be clinically relevant to
monitor the hemodynamic response on NSBBs using
repeated HVPG measurements and providing additional
therapy, such as endoscopic band ligation, to non-
responding patients. However, no studies investigating the
cost-effectiveness of this strategy have been carried out
so far.
Some heterogeneity in the trial-specific characteristics of
studies included in the present meta-analysis needs to be
considered. Firstly, the time interval between remeasure-
ment of the HVPG differed between the studies. It has been
suggested previously that an early hemodynamic response
is associated with a higher ability of predicting variceal
bleeding in the long term compared with a late response
Fig. 2. Forest plot Mantel–Haenszel fixed-effects model for the relative risk of variceal bleeding in hemodynamic responders on primary prophylaxis with
nonselective β-blocker therapy. CI, confidence interval.
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[14]. In addition, it has been found that the hemodynamic
response to NSBBs changes after long-term follow-up in
about 20% of patients [38]. However, in the present study,
no correlation was found between bleeding risk and the
median time to the second HVPG measurement.
Therefore, we could not identify the optimal time interval
for remeasurement on the basis of these data. Second,
different techniques of HVPG measurement were used in
the studies included. Two major techniques are used in
clinical practice: the straight catheter and the balloon-
tipped catheter technique. Both methods are considered
safe and reproducible procedures [8,9], but studies have
shown that the balloon-tipped catheter technique is more
accurate in estimating portal pressure compared with the
straight catheter [39,40]. Although five out of six studies
used the balloon-tipped catheter technique, there were
differences in material brands and accessed vein. To
minimize the potential effect of the technique and the type
of materials used, standardization of these factors in future
studies should be applied. Finally, the studies included
used different inclusion criteria with respect to variceal
size, which is a major determinant for variceal bleeding
risk. Despite these differences in variceal classification, no
significant heterogeneity in RR for the risk of a first var-
iceal bleeding episode was found between the studies. The
mean baseline HVPG was ∼18mmHg in all the studies
included, which therefore mainly assessed the hemody-
namic response rate in clinically significant portal hyper-
tension. A recent study by Villanueva et al. [41] showed
that patients with subclinical portal hypertension have
significantly lower portal pressure reduction after acute β-
blockade than patients with clinical significant portal
hypertension, suggesting that NSBB therapy is more
effective in the former subgroup. Associations with
bleeding risk of other relevant trial-level covariates, such as
severity and etiology of cirrhosis, follow-up time, and
treatment dose, could not be analyzed in this meta-analysis
because individual patient data were not described in all
papers. The effect of a hemodynamic response to NSBB
prophylaxis on liver-related mortality was not assessed in
all studies either.
Currently, traditional NSBBs (i.e. propranolol and
nadolol) as well as carvedilol are recommended for pri-
mary prophylactic therapy [4]. Carvedilol seems to be
more effective in decreasing HVPG than traditional NSBBs
[42] and switching to carvedilol in nonresponders to pro-
pranolol may result in the achievement of a hemodynamic
response [43]. However, adequate comparison in clinical
trials is still lacking. As none of the studies included used
carvedilol as primary prophylactic therapy, we could not
compare the effect of these β-blocker types either. Various
add-on therapies have been studied to support NSBB
therapy, such as vasodilators, diuretics, statins, and
organic nitrates. Nevertheless, sufficient evidence for
implementation of these therapies in clinical practice is
lacking. Addition of organic nitrates to NSBB therapy has
been found to increase the rate of responders by one-third
[44]. However, a previous meta-analysis showed a non-
significant lower bleeding rate, similar mortality rates, and
more adverse effects in the group of patients receiving
combined prophylactic therapy compared with patients
treated with NSBBs alone [25,45,46]. In the present meta-
analysis, combined therapy with NSBBs and organic
nitrates was performed in four studies. In two of these
studies, organic nitrates were added because of a hemo-
dynamic nonresponse to NSBBs, resulting in an additional
hemodynamic response rate of 25.6%. However, differ-
ences in the variceal bleeding risk between the mono-
therapy and the combination therapy group were not
reported.
Conclusion
Hemodynamic monitoring in primary prophylaxis seems
to be a strong prognostic tool in risk assessment for var-
iceal bleeding in cirrhosis. The ideal add-on therapy has
not been established as yet. According to the Baveno VI
consensus, measurement of HVPG response to treatment
offers relevant additional information. The cost-
effectiveness of hemodynamic monitoring and impact on
variceal bleeding incidence should be further explored in
future randomized-controlled trials.
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